200 related articles for article (PubMed ID: 2024291)
1. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.
Ford-Hutchinson AW
Trends Pharmacol Sci; 1991 Feb; 12(2):68-70. PubMed ID: 2024291
[TBL] [Abstract][Full Text] [Related]
2. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of leukotriene biosynthesis.
Ford-Hutchinson AW
Ann N Y Acad Sci; 1991; 629():133-42. PubMed ID: 1952545
[No Abstract] [Full Text] [Related]
4. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase.
Abramovitz M; Wong E; Cox ME; Richardson CD; Li C; Vickers PJ
Eur J Biochem; 1993 Jul; 215(1):105-11. PubMed ID: 8344271
[TBL] [Abstract][Full Text] [Related]
5. Linoleic acid peroxidation by Solanum tuberosum lipoxygenase was activated in the presence of human 5-lipoxygenase-activating protein.
Battu S; Moalic S; Rigaud M; Beneytout JL
Biochim Biophys Acta; 1998 Jun; 1392(2-3):340-50. PubMed ID: 9630716
[TBL] [Abstract][Full Text] [Related]
6. 5-Lipoxygenase.
Ford-Hutchinson AW; Gresser M; Young RN
Annu Rev Biochem; 1994; 63():383-417. PubMed ID: 7979243
[No Abstract] [Full Text] [Related]
7. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
[TBL] [Abstract][Full Text] [Related]
8. A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells.
Kargman S; Vickers PJ; Evans JF
J Cell Biol; 1992 Dec; 119(6):1701-9. PubMed ID: 1469057
[TBL] [Abstract][Full Text] [Related]
9. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis.
Gerstmeier J; Weinigel C; Barz D; Werz O; Garscha U
Biochim Biophys Acta; 2014 Sep; 1840(9):2961-9. PubMed ID: 24905297
[TBL] [Abstract][Full Text] [Related]
10. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
Mancini JA; Prasit P; Coppolino MG; Charleson P; Leger S; Evans JF; Gillard JW; Vickers PJ
Mol Pharmacol; 1992 Feb; 41(2):267-72. PubMed ID: 1538707
[TBL] [Abstract][Full Text] [Related]
11. 5-lipoxygenase and FLAP.
Peters-Golden M; Brock TG
Prostaglandins Leukot Essent Fatty Acids; 2003; 69(2-3):99-109. PubMed ID: 12895592
[TBL] [Abstract][Full Text] [Related]
12. Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling.
Lammers CH; Schweitzer P; Facchinetti P; Arrang JM; Madamba SG; Siggins GR; Piomelli D
J Neurochem; 1996 Jan; 66(1):147-52. PubMed ID: 8522947
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
[TBL] [Abstract][Full Text] [Related]
14. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J
J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985
[TBL] [Abstract][Full Text] [Related]
15. 5-Lipoxygenase: a target for antiinflammatory drugs revisited.
Steinhilber D
Curr Med Chem; 1999 Jan; 6(1):71-85. PubMed ID: 9873115
[TBL] [Abstract][Full Text] [Related]
16. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
[TBL] [Abstract][Full Text] [Related]
17. 5-Lipoxygenase-activating protein (FLAP).
Vickers PJ
J Lipid Mediat Cell Signal; 1995 Oct; 12(2-3):185-94. PubMed ID: 8777565
[No Abstract] [Full Text] [Related]
18. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
Bäck M
Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386
[TBL] [Abstract][Full Text] [Related]
19. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
Dixon RA; Diehl RE; Opas E; Rands E; Vickers PJ; Evans JF; Gillard JW; Miller DK
Nature; 1990 Jan; 343(6255):282-4. PubMed ID: 2300173
[TBL] [Abstract][Full Text] [Related]
20. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.
Bell RL; Young PR; Albert D; Lanni C; Summers JB; Brooks DW; Rubin P; Carter GW
Int J Immunopharmacol; 1992 Apr; 14(3):505-10. PubMed ID: 1618602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
